Publications
385 results found
Magliozzi R, Pitteri M, Ziccardi S, et al., 2021, CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis, Annals of Clinical and Translational Neurology, Vol: 8, Pages: 534-547, ISSN: 2328-9503
INTRODUCTION AND METHODS: In order to verify whether parvalbumin (PVALB), a protein specifically expressed by GABAergic interneurons, could be a MS-specific marker of grey matter neurodegeneration, we performed neuropathology/molecular analysis of PVALB expression in motor cortex of 40 post-mortem progressive MS cases, with/without meningeal inflammation, and 10 control cases, in combination with cerebrospinal fluid (CSF) assessment. Analysis of CSF PVALB and neurofilaments (Nf-L) levels combined with physical/cognitive/3TMRI assessment was performed in 110 naïve MS patients and in 32 controls at time of diagnosis. RESULTS: PVALB gene expression was downregulated in MS (fold change = 3.7 ± 1.2, P < 0.001 compared to controls) reflecting the significant reduction of PVALB+ cell density in cortical lesions, to a greater extent in MS patients with high meningeal inflammation (51.8, P < 0.001). Likewise, post-mortem CSF-PVALB levels were higher in MS compared to controls (fold change = 196 ± 36, P < 0.001) and correlated with decreased PVALB+ cell density (r = -0.64, P < 0.001) and increased MHC-II+ microglia density (r = 0.74, P < 0.01), as well as with early age of onset (r = -0.69, P < 0.05), shorter time to wheelchair (r = -0.49, P < 0.05) and early age of death (r = -0.65, P < 0.01). Increased CSF-PVALB levels were detected in MS patients at diagnosis compared to controls (P = 0.002). Significant correlation was found between CSF-PVALB levels and cortical lesion number on MRI (R = 0.28, P = 0.006) and global cortical thickness (R = -0.46, P < 0.001), better than Nf-L levels. CSF-PVALB levels increased in MS patients with severe cognitive impairment (mean ± SEM:25.2 ± 7.5
Horby PW, Roddick A, Spata E, et al., 2021, Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet, Vol: 397, Pages: 605-612, ISSN: 0140-6736
BackgroundAzithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.MethodsIn this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospital with COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients were randomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once per day by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatment groups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment and were twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants and local study staff were not masked to the allocated treatment, but all others involved in the trial were masked to the outcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.FindingsBetween April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) were eligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was 65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomly allocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall, 561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days (rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No
Salter A, Stahmann A, Ellenberger D, et al., 2021, Data harmonization for collaborative research among MS registries: A case study in employment, MULTIPLE SCLEROSIS JOURNAL, Vol: 27, Pages: 281-289, ISSN: 1352-4585
- Author Web Link
- Cite
- Citations: 10
Evangelou N, Garjani A, dasNair R, et al., 2021, Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol: 92, Pages: 107-+, ISSN: 0022-3050
- Author Web Link
- Cite
- Citations: 31
das Nair R, Hunter R, Garjani A, et al., 2021, Challenges of developing, conducting, analysing and reporting a COVID-19 study as the COVID-19 pandemic unfolds: an online co-autoethnographic study, BMJ OPEN, Vol: 11, ISSN: 2044-6055
- Author Web Link
- Cite
- Citations: 3
Garjani A, Hunter R, Nicholas R, et al., 2020, Anxiety affects the general well-being of people with ms during the COVID-19 pandemic more than the infection itself, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 65-65, ISSN: 1352-4585
Vickaryous N, Garjani A, Jacobs B, et al., 2020, Vitamin D levels in the UK MS population and COVID-19 susceptibility, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 55-55, ISSN: 1352-4585
- Author Web Link
- Cite
- Citations: 1
Rahn AC, Solari A, Beckerman H, et al., 2020, 'I will respect the autonomy of my patient': current stage of research to facilitate shared decision-making in multiple sclerosis, RIMS Digital Conference, Publisher: SAGE PUBLICATIONS LTD, Pages: 39-39, ISSN: 1352-4585
Di Bella C, Trender W, Hellyer P, et al., 2020, Evaluating cognitive functioning in multiple sclerosis, compared to other neurological disorders, using an online cognitive battery, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 502-503, ISSN: 1352-4585
Dorsey-Campbell R, Radia C, Hill J, et al., 2020, Early monitoring of b cells on ocrelizumab may help to identify those at risk of adverse effects, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 273-274, ISSN: 1352-4585
Hillert J, Forsberg L, Manouchehrinia A, et al., 2020, Ongoing disease modifying treatment associated with mis-classification of secondary progressive as relapsing-emitting multiple sclerosis Pharmacological management of progressive MS, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 20-21, ISSN: 1352-4585
- Author Web Link
- Cite
- Citations: 2
Barritt A, Das E, Morley N, et al., 2020, Novel treatment approach for fingolimod-associated progressive multifocal leukoencephalopathy in a patient with relapsing remitting multiple sclerosis, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 294-294, ISSN: 1352-4585
- Author Web Link
- Cite
- Citations: 1
Das J, Nicholas R, Middleton R, et al., 2020, The impact of socioeconomic status on the access to disease modifying therapy in people with multiple sclerosis, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 357-358, ISSN: 1352-4585
Nicholas R, Dobay P, Lacinova K, et al., 2020, ENTIMOS: A discrete event simulation model for maximizing efficiency of infusion suites in centres treating multiple sclerosis patients, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 121-122, ISSN: 1352-4585
- Author Web Link
- Cite
- Citations: 1
Forsberg L, Glaser A, Manouchehrinia A, et al., 2020, Validation of three secondary progressive multiple sclerosis classification methods in five registries within the SPMS research collaboration network Pharmacological management of progressive MS, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 19-19, ISSN: 1352-4585
- Author Web Link
- Cite
- Citations: 1
Middleton R, Evangelou N, Garjani A, et al., 2020, Clinical COVID19 data collection from the uk multiple sclerosis register, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 63-64, ISSN: 1352-4585
Glaser A, Forsberg L, Manouchehrinia A, et al., 2020, Objective classification methods result in an increased proportion of secondary progressive multiple sclerosis in five patient registries, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 348-348, ISSN: 1352-4585
Garjani A, Evangelou N, Das Nair R, et al., 2020, COVID-19 in people with MS: a large community-based study of the UK MS register, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 46-47, ISSN: 1352-4585
- Author Web Link
- Cite
- Citations: 1
Rigoni E, Singh-Curry V, Nandoskar A, et al., 2020, Real world evidence of progression independent of relapsing activity among ms patients treated with alemtuzumab, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 547-547, ISSN: 1352-4585
- Author Web Link
- Cite
- Citations: 1
Dorsey-Campbell R, Radia C, Dewan A, et al., 2020, Reported COVID19 symptoms in patients on oral disease modifying treatmentss (DMTS) at a single centre, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 60-61, ISSN: 1352-4585
Neo C, Singh-Curry V, Nandoskar A, et al., 2020, Real-world data on the use of ocrelizumab, among ms patients: b-cell suppression and clinical outcomes, 8th Joint ACTRIMS-ECTRIMS Meeting (MSVirtual), Publisher: SAGE PUBLICATIONS LTD, Pages: 185-186, ISSN: 1352-4585
- Author Web Link
- Cite
- Citations: 1
Monaco S, Nicholas R, Reynolds R, et al., 2020, Intrathecal inflammation in progressive multiple sclerosis, International Journal of Molecular Sciences, Vol: 21, Pages: 1-11, ISSN: 1422-0067
Progressive forms of multiple sclerosis (MS) are associated with chronic demyelination, axonal loss, neurodegeneration, cortical and deep gray matter damage, and atrophy. These changes are strictly associated with compartmentalized sustained inflammation within the brain parenchyma, the leptomeninges, and the cerebrospinal fluid. In progressive MS, molecular mechanisms underlying active demyelination differ from processes that drive neurodegeneration at cortical and subcortical locations. The widespread pattern of neurodegeneration is consistent with mechanisms associated with the inflammatory molecular load of the cerebrospinal fluid. This is at variance with gray matter demyelination that typically occurs at focal subpial sites, in the proximity of ectopic meningeal lymphoid follicles. Accordingly, it is possible that variations in the extent and location of neurodegeneration may be accounted for by individual differences in CSF flow, and by the composition of soluble inflammatory factors and their clearance. In addition, “double hit” damage may occur at sites allowing a bidirectional exchange between interstitial fluid and CSF, such as the Virchow–Robin spaces and the periventricular ependymal barrier. An important aspect of CSF inflammation and deep gray matter damage in MS involves dysfunction of the blood–cerebrospinal fluid barrier and inflammation in the choroid plexus. Here, we provide a comprehensive review on the role of intrathecal inflammation compartmentalized to CNS and non-neural tissues in progressive MS.
Rahn AC, Solari A, Beckerman H, et al., 2020, “I Will Respect the Autonomy of My Patient” A Scoping Review of Shared Decision Making in Multiple Sclerosis, International Journal of MS Care, Vol: 22, Pages: 285-293, ISSN: 1537-2073
Activity Available Online: To access the article, post-test, and evaluation online, go to http://www.cmscscholar.org. Target Audience: The target audience for this activity is physicians, physician assistants, nursing professionals, and other health care providers involved in the management of patients with multiple sclerosis (MS).
Cottrell L, Economos G, Evans C, et al., 2020, A realist review of advance care planning for people with multiple sclerosis and their families, PLOS ONE, Vol: 15, ISSN: 1932-6203
- Author Web Link
- Cite
- Citations: 11
Wilkie D, Solari A, Nicholas R, 2020, The impact of the face-to-face consultation on decisional conflict in complex decision-making in multiple sclerosis: a pilot study, Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol: 6, Pages: 1-11, ISSN: 2055-2173
BackgroundThe role of face-to-face consultations in medicine is increasingly being challenged. Disease activity, national guidelines, life goals e.g. pregnancy, multiple therapies and side effects need to be considered on starting disease modifying treatments (DMTs) in people with multiple sclerosis (pwMS). ObjectivesWe studied the impact of a face-to-face consultation on decision making, using decisional conflict (DC) as the primary outcome. MethodsProspective cohort study of 73 pwMS attending clinics who were making decisions about DMTs followed for one year. Prerequisites and consultation features were measured with the SURE scale for DC used as the primary outcome at baseline and at one year.ResultsThe patient activation measure (PAM) was the only driver prior to the consultation associated with DC (p=0.02) showing those less engaged were more likely to have DC. Overall, 51/73 (70%) of people made their treatment decision or reinforced a former decision during the consultation. We found making a treatment decision between the original consultation and the follow-up was associated with resolving DC (p=0.008).Conclusions Patient engagement impacts DC but the HCP delivering the optimal Shared Decision Making (SDM) approach is additionally significant in reducing DC. In complex decisions there is a clear role for face-to-face consultations in current practice.
Middleton RM, Pearson OR, Ingram G, et al., 2020, A Rapid Electronic Cognitive Assessment Measure for Multiple Sclerosis: Validation of Cognitive Reaction, an Electronic Version of the Symbol Digit Modalities Test, JOURNAL OF MEDICAL INTERNET RESEARCH, Vol: 22, ISSN: 1438-8871
- Author Web Link
- Cite
- Citations: 6
Peeters LM, Parciak T, Walton C, et al., 2020, COVID-19 in people with multiple sclerosis: A global data sharing initiative, MULTIPLE SCLEROSIS JOURNAL, Vol: 26, Pages: 1157-1162, ISSN: 1352-4585
- Author Web Link
- Cite
- Citations: 43
Martin N, Sovetkina A, Nadir R, et al., 2020, Development of autoimmune thyroid disease in multiple sclerosis patients post-alemtuzumab improves treatment response, The Journal of Clinical Endocrinology & Metabolism, Vol: 105, Pages: e3392-e3399, ISSN: 0021-972X
ContextAlemtuzumab is an anti-CD52 monoclonal antibody used in the treatment of relapsing-remitting multiple sclerosis (MS). Between 20-40% of alemtuzumab-treated MS patients develop autoimmune thyroid disease (AITD) as a side effect.ObjectiveTo determine whether MS disease progression following alemtuzumab treatment differs in patients that develop AITD compared to those who do not.Design, setting and patientsA retrospective analysis of 126 patients with relapsing-remitting MS receiving alemtuzumab from 2012 to 2017 at a tertiary referral centre.Main outcome measuresThyroid status, new relapses, Expanded Disability Status Score (EDSS) change and disability progression following alemtuzumab were evaluated.ResultsTwenty-six percent (33 out of 126, 25 female, 8 male) of alemtuzumab-treated patients developed AITD, 55% of which was Graves’ disease. EDSS score following alemtuzumab was reduced in patients who developed AITD compared to those who did not (median [IQR]; AITD: -0.25 [-1 - 0.5] vs non-AITD: 0 [1 - 0]. P=0.007]. Multivariate regression analysis confirmed that the development of AITD was independently associated with EDSS score improvement (p=0.011). Moreover, AITD patients had higher relapse-free survival following alemtuzumab (p=0.023). There was no difference in the number of new focal T2-lesions and contrast-enhancing MRI lesions developed following alemtuzumab between the two groups.ConclusionGraves’ disease was the most common form of AITD developed by MS patients following alemtuzumab. This study suggests that MS patients who develop AITD may have an improved response to alemtuzumab, as measured by reduced disability and lower relapse rate.
Nicholas R, Brooks D, Owen D, 2020, 18F-GE180, a radioligand for the TSPO protein: not ready for clinical trials in multiple sclerosis, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol: 47, Pages: 2242-2243, ISSN: 1619-7070
- Author Web Link
- Cite
- Citations: 2
Samjoo IA, Worthington E, Haltner A, et al., 2020, Matching-adjusted indirect treatment comparison of siponimod and other disease modifying treatments in secondary progressive multiple sclerosis, CURRENT MEDICAL RESEARCH AND OPINION, Vol: 36, Pages: 1157-1166, ISSN: 0300-7995
- Author Web Link
- Cite
- Citations: 10
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.